Episode Details

AstraZeneca and Bristol Myers Squibb are rumored to be eyeing a $400 billion merger that could birth the world’s biggest drugmaker — but markets reacted the opposite of expected: AstraZeneca’s stock plunged 7%, while Bristol Myers soared to a 52-week high. Why? Bristol Myers is bracing for a patent cliff on blockbuster drugs like Eliquis and Opdivo, making a merger a potential lifeline to absorb future revenue losses. AstraZeneca shareholders are skeptical — they already have a stellar pipeline and see no need to merge with a company facing looming patent expirations. Plus, regulators would likely demand divestitures of overlapping cancer drugs, slashing deal value and dragging out approvals. With both companies set to report earnings in late October, investors are watching closely — if talks collapse, stocks may reverse course.

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/fc7165e9d06e9577